Publications
135
Citations
6,025
Est. group size
—
Recurring co-author estimate
Active years
40
Publishing since 1986
Richard Shell's work focuses on the respiratory and clinical care of children with neuromuscular diseases, particularly Duchenne muscular dystrophy and spinal muscular atrophy (SMA). His publications cover treatment guidelines, gene therapy outcomes (such as onasemnogene abeparvovec for SMA), and consensus-building studies (using methods like the Delphi technique) to standardize care and diagnostic criteria for breathing problems in these conditions.
Publication output has fluctuated over the last decade, with peaks around 2017-2020 and 2025, but a lower average pace (about 5-6 papers/year) in the most recent five years compared to earlier years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- 625P"Your baby has Duchenne. What next?” Validation of a treatment framework for early-diagnosed Duchenne muscular dystrophy using the Delphi method
Neuromuscular Disorders · 2025
- MSR177 Qualitative Analysis of Results From a Delphi Study to Formalize a Treatment Protocol for Children With Early Diagnosed Duchenne Muscular Disease (DMD) Using Giles®, an Artificial Intelligence Agent for Healthcare Research
Value in Health · 2025
- Respiratory Insufficiency in Neuromuscular Disease (RIND): A Delphi Study to Establish Consensus Criteria to Define and Diagnose Hypoventilation in Pediatric Neuromuscular Disease
Journal of Neuromuscular Diseases · 2023
- Bulbar Function in Children with Two or Three SMN2 Copies Who Received Onasemnogene Abeparvovec Presymptomatically for Spinal Muscular Atrophy (P7-9.008)
Neurology · 2023
- Disease-modifying pharmacotherapies
Elsevier eBooks · 2023
- Developing a Novel Pulmonary Assessment Module for Spinal Muscular Atrophy
2023
- Regional tree-ring oxygen isotope deduced summer monsoon drought variability for Kumaun-Gharwal Himalaya
Quaternary Science Reviews · 2022
- S11 Long-term follow-up of the phase 1 START trial of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1
2021
- The respiratory impact of novel therapies for spinal muscular atrophy
Pediatric Pulmonology · 2020
- The Use Of Six Sigma To Improve The Quality Of Engineering Education
2020
- Effectiveness of Airway Clearance in Duchenne Muscular Dystrophy
2020
- Thérapie génique (TG) dans l’amyotrophie spinale de type 1 (SMA1) : suivi à long terme (SLT) de l’essai clinique de phase 1 évaluant l’onasemnogène abeparvovec
Revue Neurologique · 2020
- S61 Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): preliminary pulmonary and ventilatory findings from the phase 3 study (STR1VE)
2019
- Respiratory Management of the Patient With Duchenne Muscular Dystrophy
PEDIATRICS · 2018
- Neuromuscular Disorders×16
- Neurology×10
- Pediatric Pulmonology×6
- CHEST Journal×5
- Pediatric Neurology×3
- Arthur H.M. Burghes
Medicine · The Ohio State University
- Megan A. Waldrop
Medicine · The Ohio State University
- Anton J. Blatnik
Medicine · The Ohio State University
- Kathrin Meyer
Medicine · The Ohio State University
- Matthew E.R. Butchbach
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile